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Abstract
Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin–Angiotensin System 
inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed 
once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 
epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and 
antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental 
models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. 
Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treat-
ments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online 
questionnaire to collect relevant data in human disease.
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1 Introduction
The recent Severe Acute Respiratory Syndrome (SARS) due 
to Coronavirus 2 (CoV-2) infection pandemic and subse-
quent spread of the disease called COVID-19 brought back 
to discussion a topic already highlighted during the SARS-
CoV-1 and Coronavirus-related SARS known as the Middle 
East Respiratory Distress Syndrome (MERS) of 2002 and 
2013. During those outbreaks it was observed a particularly 
elevated incidence of cardiovascular disease among patients, 
who were also characterized by being elderly and, in particu-
lar during the MERS, prevalently male [1, 2].
Another main topic of the discussion is the role of the 
angiotensin-converting enzyme (ACE) 2. Indeed, this car-
boxypeptidase has been identified as a functional receptor 
for the spike protein of the coronaviruses’ outer membrane, 
including SARS-CoV-2 [3]. ACE2 is strongly expressed in 
the epithelium of different organs, such as the kidney, heart, 
and lungs.
ACE2 shares a large affinity to the amino peptidase 
ACE that is target to the ACE inhibitors, a class of antihy-
pertensive drugs. ACE inhibitors represent the most used 
class of cardiovascular agents in the world, for the treatment 
of epidemic cardiovascular conditions such as hypertension 
and heart failure. Although not directly inhibited by ACE 
inhibitors, ACE2 is affected by chronic treatment with this 
class of drugs, which leads to an increase in ACE2 expres-
sion in several tissues [4]. Interestingly, this feature is also 
shared by another class of drugs, the angiotensin receptor-1 
blockers (ARBs), whose chronic administration is as well 
able to increase the level of expression of ACE2 and also its 
activity, as assessed by the circulating levels of the ACE2 
product, angiotensin 1–7 [5]. These findings support the 
concern that the treatment with Renin-Angiotensin System 
(RAS) inhibitors could make COVID-19 symptoms more 
severe due to increased expression of ACE2.
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2  Cardiovascular Disease and COVID‑19
Remarkably, both issues have been re-proposed in the 
occurrence of the present epidemic of COVID-19. In par-
ticular, the issue of the prevalence of cardiovascular dis-
eases among COVID-19 patients is proposed by observa-
tional data obtained in Chinese [6] and Italian patients [7].
In this context, we still lack the analysis of the con-
founding effects of age on the apparent association 
between cardiovascular disease COVID-19 infection and 
clinical severity. Indeed, the observed prevalence of male 
and elderly patients, observed especially in the Italian 
COVID-19 population, is a confounding factor that needs 
to be corrected for before any conclusive association is 
drawn. This concern has been expressed by many [8–10].
Similarly, the ACE2 upregulation argument has never 
been demonstrated in humans. Indeed, while there is con-
flicting evidence from animal studies that ARBs (prob-
ably not ACE inhibitors) may upregulate membrane-bound 
ACE2 in tissue-specific manners (e.g., heart but not kid-
ney), these data cannot be extrapolated to humans, and are 
not sufficient to support facilitation of SARS-CoV-2 entry 
[9]. In particular, it has never been demonstrated that the 
ACE2 upregulation in the human lung occurs upon RAS 
inhibition, and even less that this causes a worsening of the 
COVID-19 disease. Furthermore, it can also be speculated 
that ACE2 upregulation is protective. Indeed, it has been 
shown that the binding of coronavirus to ACE2 leads to 
the downregulation of ACE2 [11], which in turn causes 
an ACE/ACE2 imbalance and to the excessive production 
of angiotensin II by the related ACE enzyme. This excess 
of Angiotensin II stimulates angiotensin II receptor type 1 
(AT1R) and might cause an increase in pulmonary vascu-
lar permeability and lung damage [12]. Therefore, accord-
ing to this hypothesis, the upregulation of ACE2, caused 
by the chronic intake of AT1R and ACE Inhibitors, could 
be protective through two mechanisms: first, by blocking 
the increased production of angiotensin 1–7, which has 
been advocated as a possible mechanism of protection for 
the lung; second, by reducing the production of Angioten-
sin II, it removes a cause of lung damage [13].
3  Recommendations
In this context of uncertainty, there are advocates within 
the scientific community raising their voices for the ces-
sation of ACE inhibitors and ARBs among patients taking 
these drugs, that is claimed for both the prevention of the 
infection and the attenuation of the symptoms in case of 
infection. These speculative claims are then taken over 
by the laical press, starting a word of mouth that sustains 
panic behaviors among the general population.
The Italian Society of Hypertension (SIIA) therefore 
takes a clear and firm position, in line with statements by 
other International Societies (See Table 1). SIIA states the 
following items: 
1. There is no evidence to associate hypertension or 
other CVDs with COVID-19 disease: if hypertension 
was a predisposing factor for coronavirus infection, 
there should be more hypertensives among COVID-19 
patients than observed in the general population; to date, 
there is no evidence that people with hypertension are 
overrepresented among those infected with COVID-19.
2. There is no clinical evidence in humans that associates 
the intake of ACE inhibitors or ARBs with COVID-19 
disease. At present we can neither say that they improve 
nor say they worsen the susceptibility to coronavirus 
infection.
3. There are no clinical data in patients that can confirm 
the harmful effect (not even the protective one) of 
ACE inhibitors and ARB in the context of the COVID-
19 epidemic.
Furthermore, SIIA reiterates that subsequent points:
A. Acute suspension without medical control of cardiovas-
cular therapy and specifically of antihypertensive treat-
ment increases the occurrence of acute events, including 
hypertensive emergencies, heart failure decompensation, 
heart attacks, and stroke.
B. The favorable effects of ACE inhibitors and ARBs on 
the control of the progression of CVDs in general and in 
particular of hypertensive patients have been confirmed 
for many years and for this reason RAS inhibitors repre-
sent central agents for the management of cardiovascular 
conditions that cannot be easily substituted [10].
C. In hypertensive patients with COVID-19 or at risk of 
COVID-19 infection, ACE inhibitors and ARBs treat-
ment should be maintained according to the recommen-
dations contained in the 2018 ESC/ESH guidelines [10].
D. Similarly, in all patients currently on therapy with ACE 
inhibitors, ARBs and in the case of patients with heart 
failure, also the ARNIs, these drugs must not be sus-
pended.
E. In patients with COVID-19 with severe symptoms or 
sepsis, ACE Inhibitors and ARBs, like all other antihy-
pertensive drugs, should be used or discontinued on a 
case by case basis, taking into account current guide-
lines.
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4  Further Scientific Research
SIIA hopes and promotes further research that analyzes the 
constantly increasing data on the impact of hypertension 
and antihypertensive drugs, in particular ACE inhibitors and 
ARBs, on the clinical course of COVID-19 infections, in 
order to update these positions as new evidence becomes 
available.
In particular, to clarify which mechanism is prevalent and 
has a role in the clinical manifestation of COVID-19, SIIA 
has launched a fact-finding investigation to verify the impact 
of therapy with inhibitors of the renin-angiotensin system on 
the onset and clinical manifestation of the disease COVID-
19. This observational research is based on an online ques-
tionnaire made of 18 questions to collect information on 
medical history and the evolution of the disease in COVID19 
patients (ID: NCT04331574; clinicaltrials.gov).
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